Početna › Kronična limfocitna leukemija › Wisconsin
Kliničke studije za Kronična limfocitna leukemija u državi Wisconsin
19 studija za Kronična limfocitna leukemija traži sudionike na lokacijama u državi Wisconsin.
Gradovi u državi Wisconsin
Službeni tekst studije (engleski)
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- Duluth Clinic Ashland, Ashland
- Saint Vincent Hospital Cancer Center Green Bay, Green Bay
- Saint Vincent Hospital Cancer Center at Saint Mary's, Green Bay
- i još 7
U tijeku regrutacijaFaza 3
Od 65 godina i više · Oba spola · Ažurirano 2. lis 2026. · NCT07321652Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Aspirus Cancer Care-Antigo-Volm Cancer Center, Antigo
- ThedaCare Regional Cancer Center, Appleton
- ThedaCare Regional Medical Center - Appleton, Appleton
- i još 50
U tijeku regrutacijaOpažajna studijaZdravi dobrovoljci dobrodošli
Od 40 do 75 godina · Oba spola · Ažurirano 2. lis 2026. · NCT05334069Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Aspirus Cancer Care-Antigo-Volm Cancer Center, Antigo
- Duluth Clinic Ashland, Ashland
- Marshfield Medical Center-EC Cancer Center, Eau Claire
- i još 14
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 30. ruj 2026. · NCT04269902A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
- Medical College of Wisconsin, Milwaukee
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT07277231A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Gunderson Health System, La Crosse
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT06973187A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- SSM Health Dean Medical Group - South Madison Campus Health Research/Circuit Clinical ( Site 0048), Madison
- University Hospital and UW Health Clinics ( Site 0006), Madison
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 24. ruj 2026. · NCT06136559Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Medical College of Wisconsin, Milwaukee
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 21. ruj 2026. · NCT07648264A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- The Medical College of Wisconsin, Milwaukee
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 17. ruj 2026. · NCT07221500Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Medical College of Wisconsin, Milwaukee
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 8. ruj 2026. · NCT03666000A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Medical College of Wisconsin, Milwaukee
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 2. srp 2026. · NCT05131022Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial
- Medical College of Wisconsin, Milwaukee
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 13. ožu 2026. · NCT07218510A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
- Medical College of Wisconsin, Milwaukee
U tijeku regrutacijaFaza 4
Od 18 godina i više · Oba spola · Ažurirano 2. ožu 2026. · NCT06876662A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
- Medical College of Wisconsin, Milwaukee
U tijeku regrutacijaFaza 4
Od 18 godina i više · Oba spola · Ažurirano 2. ožu 2026. · NCT06876649CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
- Medical College of Wisconsin and Froedtert Hospital, Milwaukee
U tijeku regrutacijaFaza 1/2
Od 18 do 80 godina · Oba spola · Ažurirano 23. velj 2026. · NCT04186520Study of SGR-1505 in Mature B-Cell Neoplasms
- Medical College of Wisconsin, Milwaukee
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 13. velj 2026. · NCT05544019AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- The Medical College of Wisconsin, Milwaukee
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 10. pro 2025. · NCT05602363In Vivo Metabolic Profiling of CLL (Chronic Lymphocytic Leukemia)
- University of Wisconsin, Madison
U tijeku regrutacijaOpažajna studijaZdravi dobrovoljci dobrodošli
Od 18 godina i više · Oba spola · Ažurirano 26. stu 2025. · NCT04785989Long-term Follow-up Study of Patients Receiving CAR-T Cells
- Froedtert Hospital & Medical College of Wisconsin, Milwaukee
U tijeku regrutacijaOpažajna studija
Od 18 do 80 godina · Oba spola · Ažurirano 10. stu 2025. · NCT03375619A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
- Center for International Blood and Marrow Transplant Research (CIBMTR), Milwaukee
U tijeku regrutacijaOpažajna studija
Od 18 godina i više · Oba spola · Ažurirano 24. velj 2025. · NCT06788639Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.